We used potentially novel CSF biomarkers of AD as endophenotypes (p‐tau199, p‐tau231, and VILIP‐1), while previous studies testing the association of MAPT polymorphisms with AD used only core CSF biomarkers as endophenotypes (Aβ1–42, t‐tau, p‐tau181). The gene discussed is MAPT; the disease is Alzheimer disease.